DAT/Dopamine Transporter/SLC6A3 Antibody (hDAT-LOOP): sc-58517

DAT Antibody (hDAT-LOOP) is a rat monoclonal IgG2a antibody that detects dopamine transporter (DAT) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry with paraffin-embedded sections (IHCP). Anti-DAT antibody (hDAT-LOOP) plays a crucial role in studying the regulation of dopamine levels in the synaptic cleft, which is essential for maintaining proper neurotransmission and overall brain function. DAT (hDAT-LOOP) monoclonal antibody facilitates research on dopamine reuptake from the synaptic cleft back into presynaptic neurons, helping to terminate dopamine signaling and prevent excessive stimulation of dopamine receptors. This process is particularly important in studying neuropsychiatric disorders, where dysregulation of dopamine signaling is implicated in conditions such as schizophrenia, depression, and addiction. DAT (hDAT-LOOP) antibody provides reliable detection and characterization of DAT, enabling researchers to explore its role in various physiological and pathological processes, including interactions with other proteins that modulate dopamine signaling and its potential as a therapeutic target in dopamine-related disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DAT/Dopamine Transporter/SLC6A3 Antibody (hDAT-LOOP) References:

1. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo.  |  Lamensdorf, I., et al. 1999. Br J Pharmacol. 126: 997-1002. PMID: 10193780
2. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue.  |  Ukairo, OT., et al. 2005. J Pharmacol Exp Ther. 314: 575-83. PMID: 15879005
3. Characterization of the neuronal dopamine transporter DAT in human blood platelets.  |  Frankhauser, P., et al. 2006. Neurosci Lett. 399: 197-201. PMID: 16490314
4. A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients.  |  Mané, A., et al. 2011. Psychiatry Res. 194: 79-84. PMID: 21831607
5. Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.  |  Hall, FS., et al. 2014. Neuropharmacology. 76 Pt A: 146-55. PMID: 23978383
6. Acute blockade of the Caenorhabditis elegans dopamine transporter DAT-1 by the mammalian norepinephrine transporter inhibitor nisoxetine reveals the influence of genetic modifications of dopamine signaling in vivo.  |  Bermingham, DP., et al. 2016. Neurochem Int. 98: 122-8. PMID: 26850478
7. No effect of sex on ethanol intake and preference after dopamine transporter (DAT) knockdown in adult mice.  |  Bahi, A. and Dreyer, JL. 2019. Psychopharmacology (Berl). 236: 1349-1365. PMID: 30539268
8. Increased Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Expression in Adolescent Brain Development: A Longitudinal Micro-PET/CT Study in Rodent.  |  Jiang, D., et al. 2018. Front Neurosci. 12: 1052. PMID: 30697146
9. Simulations of a Multi-Pinhole SPECT Collimator for Clinical Dopamine Transporter (DAT) Imaging.  |  Könik, A., et al. 2018. IEEE Trans Radiat Plasma Med Sci. 2: 444-451. PMID: 31011693
10. Experimental evaluation of absolute quantification in 99m Tc-TRODAT-1 SPECT/CT brain dopamine transporter (DAT) studies.  |  Zainudin, NA., et al. 2022. J Appl Clin Med Phys. 23: e13723. PMID: 35833589

The preferred DAT/Dopamine Transporter/SLC6A3 antibody is DAT/Dopamine Transporter/SLC6A3 Antibody (6-5G10): sc-32258.